By contrast, in our case, although entrectinib was administered as the first TRK multikinase inhibitor and her tumor became resistant to entrectinib and progressed, subsequent administration of larotrectinib, a highly selective TRK inhibitor, maintained stable disease for a long time. This evidence concerns the gene NTRK1 and neoplasm.